Formulation

Details Formulation Formulation

A - Human Necessities

61

K

A61K 31/565 (2006.01) A61K 9/08 (2006.01) A61K 47/00 (2006.01) A61K 47/10 (2006.01) A61K 47/14 (2006.01) A61K 47/44 (2006.01)

Patent

CA 2351004

The invention relates to a novel sustained release pharmaceutical formulation adapted for administration by injection containing the compound 7.alpha.-[9-(4,4,5,5,5- pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17.beta.- diol, which bears the international non-proprietary name fulvestrant. More particularly the invention relates to a formulation adapted for administration by injection containing the compound 7.alpha.-[9-(4,4,5,5,5- pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17.beta.- diol in solution in a ricinoleate vehicle which additionally comprises at least one alcohol and a non-aqueous ester solvent which is miscible in the ricinoleate vehicle.

L'invention concerne une nouvelle préparation pharmaceutique à diffusion retenue adaptée à l'administration par injection contenant le composé 7 alpha -[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17 beta -diol, et en particulier une préparation adaptée pour l'administration par injection contenant le composé 7 alpha -[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17 beta -diol en solution, dans un excipient ricinoléate comportant également au moins un alcool et un solvant ester non-aqueux miscible dans l'excipient ricinoléate.

Affiliated with

Also associated with

Rating

Formulation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Formulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Formulation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1922335